Future of medicine in diagnosis of disease
-
Upload
drpriyank-shah -
Category
Health & Medicine
-
view
720 -
download
1
Transcript of Future of medicine in diagnosis of disease
![Page 1: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/1.jpg)
FUTURE OF MEDICINE IN
DIAGNOSIS OF DISEASE
![Page 2: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/2.jpg)
Contents
Pharmacogenomics
Regenerative medicine
Molecular medicine
Robotic surgery
Nano technology
![Page 3: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/3.jpg)
Pharmacogenomics
![Page 4: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/4.jpg)
Pharmacogenomics
Pharmacogenetics : The study of genetically
controlled variations in drug response
Pharmacogenomics: The science that allows us
to predict a response to drugs based on an
individuals genetic makeup.
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism
and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329–2333. doi:
10.1182/blood-2005-03-1108
![Page 5: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/5.jpg)
Genetic Variability Can Affect:
Pharmacokinetics - Plasma Clearance, Delivery
of Drug or Metabolite to Target Cells,
Pharmacodynamics - The Relationship Between
the Drug Concentration & Its Therapeutic Effect.
The Likelihood of an Adverse Reaction
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism
and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329–2333. doi:
10.1182/blood-2005-03-1108
![Page 6: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/6.jpg)
ORIGIN OF
PHARMACOGENETICS
Three Discoveries in the 1950s Gave Rise to
the Discipline of Pharmacogenetics:
Primquine Sensitivity (G-6-PD Deficiency)
The Slow Metabolism of Isoniazid (Acetylation
Polymorphism & Tuberculosis
Atypical Plasma Cholinesterase Giving Rise to
Prolonged Effects of Succinylcholine (Respiratory
Apnea)
![Page 7: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/7.jpg)
BENEFITS OF
PHARMACOGENETICS
Improve Drug Choices:
Each Year, ~100,000 Americans Die of Adverse
Reactions to Medicine & ~2 Million Are Hospitalized
Pharmacogenomics Will Predict Who's Likely to
Have a Negative or Positive Reaction to a Drug
Safer Dosing Options:
Testing of Genomic Variation Improve
Determination of Correct Dose for Each Individual
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism
and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329–2333. doi:
10.1182/blood-2005-03-1108
![Page 8: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/8.jpg)
Improvement in Drug Development:
Permit Pharmaceutical Companies to Determine in
Which Populations New Drugs Will Be Effective
Decrease Health Care Costs:
Reduce Number of Deaths & Hospitalizations Due
to Adverse Drug Reactions
Reduce Purchase of Drugs Which Are Ineffective in
Certain Individuals Due to Genetic Variations
Speed Up Clinical Trials for New Drugs
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism
and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329–2333. doi:
10.1182/blood-2005-03-1108
![Page 9: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/9.jpg)
Metabolism of 6-MP
![Page 10: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/10.jpg)
Pharmacogenetics: A Case Study
Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, et al. (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual
variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8: 1545–1550. doi: 10.2217/14622416.8.11.1545
![Page 11: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/11.jpg)
Pharmacogenetics: A Case Study
Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, et al. (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual
variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8: 1545–1550. doi: 10.2217/14622416.8.11.1545
![Page 12: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/12.jpg)
Pharmacogenetics: A Case Study
![Page 13: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/13.jpg)
Genetic Analysis Permits
More rapid determination of stable therapeutic
dose.
Better prediction of dose than clinical methods
alone.
Applicable to the 70-75% of patients not in
controled anticoagulation centers.
Reduces between 4,500 and 22,000 serious
bleeding events annually.
Genetic testing now required by FDA
Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, et al. (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual
variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8: 1545–1550. doi: 10.2217/14622416.8.11.1545
![Page 14: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/14.jpg)
REGENERATIVE MEDICINE
![Page 15: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/15.jpg)
DEFINING REGENERATIVE
MEDICINE
Regenerative medicine is a heterogeneous
domain, incorporating multiple technological
avenues of investigation.
United by a shared goal of stimulating, directing
or augmenting the body’s capacity for self-repair
and regeneration.
Our approach concentrates on technologies
using novel biomaterials – living cells, genes
and bio scaffolds.
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 16: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/16.jpg)
DEFINING REGENERATIVE
MEDICINE
Excludes small molecules and biologicals (e.g.
antibodies) that aim to stimulate in vivo
regenerative action.
Basic cell culture tools/media suppliers not
included unless have specialist focus.
![Page 17: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/17.jpg)
Adult Stem Cell
Undifferentiated Cells
Found throughout the body after embryonic development
Multiply by cell division to replenish dying cells
Regenerate Damaged Tissues.
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 18: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/18.jpg)
Types of Adult Stem Cells
Hematopoietic
Mammary
Mesenchymal
Neural
Endothelial
Olfactory
Neural crest
Testicular
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 19: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/19.jpg)
Properties
Defining properties- self-renewal & potency
Lineage
Signaling pathways
Multidrug resistance
Plasticity / Transdifferentiation
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 20: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/20.jpg)
THERAPEUTIC FOCUS OF CELL
THERAPY FIRMS
Stem cells
Cell therapy
0
1
2
3
4
5
6
7
8
9
10
Stem cells
Cell therapy
![Page 21: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/21.jpg)
STEM CELL USE IN
REGENRATIVE MEDICINE
Adult (tissue) stem cells are useful in tissue and organ regeneration:
Blood-forming stem cells to regenerate blood and immune systems
Brain-forming stem cells to regenerate neuroprotective potential in brain.
Skin-forming stem cells/burns.
Skeletal muscle stem cells for muscular dystrophies.
Mesenchymal cell cultures make scar, fat, bone and cartilage; not any other tissues.
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 22: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/22.jpg)
Benefits of Adult Stem Cell
Research
Easy to obtain
Potentially limitless in supply
Patients can use their own stem cells for
treatment and therapy
Adult stem cells are politically neutral
Not offensive to any major interest group nor do
they generate controversy.
![Page 23: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/23.jpg)
TARGETED DISEASE WITH
RM
Systemic lupus erythematosus
Multiple Sclerosis
Rheumatoid Arthritis
Ulcerative Colitis
Vasculitides
Polyarteritis
Wegener’s granulomatosis
Autoimmune Hemolytic Anaemia
Type 1 Diabetes Mellitus
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 24: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/24.jpg)
Limitations of adult stem cell
The isolation of some types of ASC, for example theisolation of neural cells from a patient's brain, would beimpractical
Where a person suffers from a genetic disorder or sometypes of cancers, ASC isolated from that individual willretain the damaging genetic alterations underlying thedisease and so be of little therapeutic value
Unambiguous identification is difficult
Maintenance in culture is difficult
M. Adamczak and A. Wiecek, “The adipose tissue as an endocrine organ,” Seminars in Nephrology, vol. 33, no. 1, pp. 2–13, 2013.
![Page 25: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/25.jpg)
MOLECULAR
TECHNOLOGY
![Page 26: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/26.jpg)
MOLECULAR MEDICINE
Molecular medicine helps in
improved diagnosis of disease
earlier detection of genetic predisposition to disease
Rational drug design
Gene therapy and control systems for drugs
Pharmacogenomics "custom drugs"
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 27: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/27.jpg)
Definitions
DNA polymorphism: A DNA sequence that occurs in two or more variant
forms
DNA marker: polymorphic locus useful for mapping studies
RFLP Variation in the length of a restriction fragment detected by a
particular probe due to nucleotide changes at a restriction site
SNP: two different nucleotides appear at the same position in genomic
DNA from different individuals
DNA fingerprinting: Detection of genotype at a number of unlinked highly
polymorphic loci using one probe
Genetic testing: Testing for a pathogenic mutation in a certain gene in an
individual that indicate a person’s risk of developing or transmitting a
disease
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 28: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/28.jpg)
RFLPs
Fig. 11.7 – genetics/ Hartwell
Amplify fragment
Expose to restriction
enzyme
Gel electrophoresis
e.g : sickle-cell
genotyping with a
PCR based protocol
![Page 29: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/29.jpg)
SSLPs
Similar principles
used in detection of
RFLPs
However, no change
in restriction sites
Changes in length of
repeats
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 30: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/30.jpg)
SNPs (single nucleotide
polymorphisms)
Sites resulting from a single change in individual bp
SNP detection using allele-specific oligonucleotide
(ASOs)
Very short probes (<21 bp) specific which hybridize to one allele or other
Such probes are called ASOs
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 31: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/31.jpg)
How to identify disease
genes Identify pathology
Find families in which the disease is
segregating
Find ‘candidate gene’
Screen for mutations in segregating families
![Page 32: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/32.jpg)
How to map candidate
genes2 broad strategies have been used
A. Position independent approach (based on
knowledge of gene function)
1) biochemical approach
2) animal model approach
B. Position dependent approach (based on
mapped position)
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 33: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/33.jpg)
Position independent
approach1) Biochemical approach: when the disease protein
is known E.g. Factor VIII haemophilia
Blood-clotting cascade
in which vessel
damage causes a
cascade of inactive
factors to be converted
to active factors
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 34: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/34.jpg)
2) Animal model approach
compares animal mutant models in a phenotypically similar human
disease.
E.g. Identification of the SOX10 gene in human Waardenburg syndrome4
(WS4)Dom (dominant megacolon)
mutant mice shared phenotypic
traits similar to human patient
with WS4 (Hirschsprung disease,
hearing loss, pigment
abnormalities)
WS4 patients screened for
SOX10 mutations
confirmed the role of this gene in
WS4.
Dom mouse Hirschsprung
Morris TA, Marsh JJ, Konopka R, Pedersen CA and Chiles PG. Improved imaging of deep venous thrombi during anticoagulation
using radiolabelled anti-D-dimer antibodies. Nucl Med Commun 2004; 25: 917-922.
![Page 35: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/35.jpg)
B) Positional dependent approach
Positional cloning
identifies a disease gene
based on only
approximate
chromosomal location. It
is used when nature of
gene product / candidate
genes is unknown.
Candidate genes can be
identified by a
combination of their map
position and expression,
function or homology
![Page 36: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/36.jpg)
Robotic surgery
![Page 37: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/37.jpg)
What is robots?
The term robots was introduced and coined in a 1921 play Rossoms Universal Robots by Karel Capek of Czech.
from the Czech ”robota” meaning forced labor, Meaning evolved into dumb machines that perform
menial repetitive tasks to the highly intelligent robots of popular culture.
Today robots are used to perform highly specific, highly precise, and dangerous tasks in industry and research previously not possible with a human work force.
Robotics, however, has been slow to enter the field of medicine and surgery
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 38: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/38.jpg)
Robotic surgery started in 2000 with adult
surgery – mainly urology
The surgeon does the surgery - not the robot
No robot (yet) to clean the instruments
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 39: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/39.jpg)
History of robotics
The first documented use of a robot-assisted surgical procedure occurred in 1985.
PUMA 560 robotic surgical arm was used successfully in a delicate neurosurgical biopsy, a non-laparoscopic surgery.
The robotic system allowed the potential for greater precision when used in minimally invasive surgeries, such as laparoscopies which typically utilize flexible fiber optic cameras.
![Page 40: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/40.jpg)
The 1985 procedure lead to the first laparoscopic procedure involving a robotic system, a cholecystectomy, in 1987.
The following year the same PUMA system was used to perform a transurethral resection.
In 1990 the AESOP system produced by Computer Motion became the first system approved by the Food and Drug Administration (FDA) for its endoscopic surgical procedure.
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 41: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/41.jpg)
Types of Robots
Passive
Retractor system
Position the tool and then hold
Active
Robot would actively move the tool upon the
surgeons command
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 42: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/42.jpg)
Surgical Robots in 2007
AESOP (Automated Endoscopic System for Optimal Positioning)
Voice activated mechanical arm
Steadier than human, never tires
daVinci
FDA approval in 2002
Laparoscopic instrumentation controlled by the surgeon positioned remotely at a console
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 43: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/43.jpg)
Development of daVinci
Defense Advanced Research Projects Agency (DARPA) for military research of remote battlefield surgery
Cholecystectomy performed remotely via telesurgery from 300 miles away
Intuitive Surgical created in 1999 after acquiring patent rights from military
First robotic prostatectomy performed in 2001Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 44: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/44.jpg)
Remote Transatlantic
Telesurgery
![Page 45: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/45.jpg)
Advantages of daVinci Robot
Magnified (12x), stereoscopic 3-D vision
Robotic wrist with 6 degrees of freedom
Movements are scaled, filtered, translated
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 46: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/46.jpg)
daVinci Robotic System
![Page 47: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/47.jpg)
Disadvantages of daVinci Robot
Expensive
- $1.4 million cost for machine
- $120,000 annual maintenance contract
- Disposable instruments $2000/case
- Hospital reimbursement same DRG
Steep surgical learning curve
Increased staff training/competance
Increased OR set-up/turnover time
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 48: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/48.jpg)
Future of...(20+ Years)
Socrates - allows surgeons at remote sites to connect to an operating room and share video and audio, to use a “telestrator” to highlight anatomy, and to control the AESOP endoscopic camera. expanding the use of preoperative (computed tomography or magnetic resonance) and intraoperative video image fusion to better guide the surgeon in dissection and identifying pathology
NANOROBOTS (less than 1000 nanometers) are in development in the medical field to be inserted into our bodies and perform surgeries on a molecular level within our bodies and repair us as a mechanic would a vehicle. (VIDEOS) reference to possibilities.
Blanco FJ. Robotic radical prostatectomy: present and future. Arch Esp Urol 2011;64(8):839-46.
![Page 49: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/49.jpg)
Nano technology
![Page 50: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/50.jpg)
Nanomedicine may be defined as the monitoring, repair,
construction and control of human biological systems at
the molecular level, using engineered nanodevices and
nanostructures.
Nanotechnology Thorough, inexpensive control of the
structure of matter based on molecule-by-molecule
control of products and by products; the products and
processes of molecular manufacturing, including
molecular machinery.
Betzig,E.,Patterso,G.H.,Sougrat,R.,Lindwasser,Q.W.,Olenych,S.,Bonifacino, J.S.,etal.(2006).Imaging intra cellular fluorescent
proteins at nanometer resolution. Science 313, 1642–1645doi:10.1126/science.1127344
![Page 51: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/51.jpg)
Nanosurgery A generic term including molecular repair
and cell surgery.
Nanodentistry The maintenance of comprehensive oral
health by employing nanomaterials, biotechnology
including tissue engineering and dental nanorobotics.
Bio-nanomaterial science Materials which are in direct
contact with biological fluids or living tissue, with minimal
adverse reaction or rejection by the body.
Nanomachine An artificial molecular machine of the sort
made by molecular manufacturing.
Betzig,E.,Patterso,G.H.,Sougrat,R.,Lindwasser,Q.W.,Olenych,S.,Bonifacino, J.S.,etal.(2006).Imaging intra cellular fluorescent
proteins at nanometer resolution. Science 313, 1642–1645doi:10.1126/science.1127344
![Page 52: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/52.jpg)
Nano technology can be used
for
Biomaterials
Bone
Teeth
Cells
Cartilage
Immune system
Viral and bacterial attack
Drug delivery
DiagnosticsBetzig,E.,Patterso,G.H.,Sougrat,R.,Lindwasser,Q.W.,Olenych,S.,Bonifacino, J.S.,etal.(2006).Imaging intra cellular fluorescent
proteins at nanometer resolution. Science 313, 1642–1645doi:10.1126/science.1127344
![Page 53: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/53.jpg)
Nano materials
Orthopedic prostheses such as total knee and hip joint
replacements, spinal implants, bone ixators, and tendon
and ligament prostheses;
Cardiovascular implants such as artificial heart valves,
vascular grafts and stents, pacemakers, and implantable
defibrillators;
Neural implants (e.g., cochlear implants) and
cerebrospinal fluid drainage systems (e.g.,
hydrocephalus shunts);
Plastic and reconstructive implants such as breast
augmentation or reconstruction, maxillofacial
reconstruction, artificial larynx, penile implants, and
injectable collagen for soft tissue augmentation;
Bartko,A.P.,andDickson,R.M.(1999b).Three-dimension al orientations of polymer-bound single molecules. J. Phys. Chem.B 103, 3053–
3056.doi: 10.1021/jp9846330
![Page 54: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/54.jpg)
Dental implants to replace teeth/root systems and bony tissue in the oral cavity;
Ophthalmic systems including contact and intraocular lenses;
Catheters and bladder stimulators;
Drug-dispensing implants such as insulin pumps;
General surgical systems such as sutures, staples, adhesives, and blood substitutes.Bartko,A.P.,andDickson,R.M.(1999b).Three-dimension al orientations of polymer-bound single molecules. J. Phys. Chem.B 103, 3053–
3056.doi: 10.1021/jp9846330
![Page 55: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/55.jpg)
Nanotechnology will contribute to a wide range
of diagnostic applications through the
development of:
Implantable Diagnostic Devices
Internal Diagnostics
Intracellular Diagnostics
Pathogen Detection
Bartko,A.P.,andDickson,R.M.(1999b).Three-dimension al orientations of polymer-bound single molecules. J. Phys. Chem.B 103, 3053–
3056.doi: 10.1021/jp9846330
![Page 56: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/56.jpg)
New Applications of
Biosensors Stent Monitor
Restenosis
Pressure gradients
Plaque build-up
Artery thickening
Smart Catheter
Fibrillation Detection
Post-operative Patient Monitoring
Drug Delivery
Bartko,A.P.,andDickson,R.M.(1999b).Three-dimension al orientations of polymer-bound single molecules. J. Phys. Chem.B 103, 3053–
3056.doi: 10.1021/jp9846330
![Page 57: Future of medicine in diagnosis of disease](https://reader033.fdocuments.us/reader033/viewer/2022051710/5a6565ef7f8b9af13a8b4813/html5/thumbnails/57.jpg)